{"id":"W3184251505","doi":"10.1016/j.cllc.2021.07.002","title":"Safety and Clinical Activity of Atezolizumab Plus Ipilimumab in Locally Advanced or Metastatic Non–Small Cell Lung Cancer: Results From a Phase 1b Trial","year":2021,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche; Roche","keywords":"Atezolizumab; Medicine; Ipilimumab; Internal medicine; Tolerability; Lung cancer; Adverse effect; Oncology; Population; Common Terminology Criteria for Adverse Events; Cancer; Nivolumab; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001715708,0.0004030253,0.002074182,0.00008925253,0.00007449672,0.00002686781,0.0002200187,0.0003945803,0.0005020007],"category_scores_gemma":[0.001241159,0.0003230901,0.0005940626,0.0005518882,0.0004538926,0.0001365877,0.0001580884,0.0009762831,0.0000020458],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006121422,"about_ca_system_score_gemma":0.004781746,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002706956,"about_ca_topic_score_gemma":0.008422268,"domain_scores_codex":[0.9943099,0.0006483243,0.002880289,0.001205256,0.000427345,0.0005288921],"domain_scores_gemma":[0.9943683,0.003293499,0.0008770983,0.0008132337,0.0002706991,0.0003771725],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7542409,0.003431278,0.005356836,0.000360525,0.001030504,0.0003120193,0.000255749,0.00004360722,0.001463325,0.000001757979,0.0009888354,0.2325146],"study_design_scores_gemma":[0.9236029,0.005073076,0.03476788,0.002612897,0.002216735,0.00001099941,0.0002043107,0.01788353,0.004119433,0.00001724153,0.008835979,0.0006549627],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9812016,0.0106182,0.0004664793,0.001534528,0.002299597,0.002145469,0.001297363,0.00004065434,0.0003960436],"genre_scores_gemma":[0.9452883,0.04898624,0.001361527,0.001258305,0.0009029971,0.000180515,0.0001363162,0.00007107502,0.001814708],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2318597,"threshold_uncertainty_score":0.9999221,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05774961993168776,"score_gpt":0.4387506707119048,"score_spread":0.3810010507802171,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}